Tuberculosis (TB) infection is a common infection. An estimated one-quarter of the world’s population is infected. People with TB infection are at risk of developing TB disease.
This risk depends on multiple factors, the most important being the state of their immune system.
A total of 1.4 million people died from TB in 2019 (including 208 000 people with HIV).
Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS).
In 2019, an estimated 10 million people fell ill with tuberculosis (TB) worldwide. 5.6 million men, 3.2 million women and 1.2 million children. It is present in all countries and age groups.
In 2019, 1.2 million children fell ill with TB globally. Child and adolescent TB is often overlooked by health providers and can be difficult to diagnose and treat.
In 2019, the 30 high TB burden countries accounted for 87% of new TB cases.
There are eight countries that accounts for two thirds of the total, with India leading the count, followed by Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa.
Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat.
A global total of 206 030 people with multidrug- or rifampicin-resistant TB (MDR/RR-TB) were detected and notified in 2019, a 10% increase from 186 883 in 2018.
Globally, TB incidence is falling at about 2% per year and between 2015 and 2019 the cumulative reduction was 9%. This was less than half way to the End TB Strategy milestone of 20% reduction between 2015 and 2020.
An estimated 60 million lives were saved through TB diagnosis and treatment between 2000 and 2019.
Ending the TB epidemic by 2030 is among the health targets of the United Nations Sustainable Development Goals (SDGs).
Is TB Treatable ?
Tuberculosis is a treatable, curable disease and most importantly preventable.
If you have been diagnosed of having TB, adhering to the treatment regimen is key to circumventing drug resistance and achieving a total cure.
For efficient prevention of tuberculosis infection, early screening and treatment for active TB is essential.
This can be achieved by addressing co-morbidities and health risks as well as social determinants of the disease, and by promoting access to universal health care.